ROY WINSTON - 06 Jun 2022 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

Role
Chief Medical Officer
Signature
/s/ Kristen Williams, Attorney-in-Fact
Issuer symbol
PCRX
Transactions as of
06 Jun 2022
Net transactions value
-$862,292
Form type
4
Filing time
08 Jun 2022, 19:48:09 UTC
Previous filing
08 Nov 2021
Next filing
05 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCRX Common Stock Sale $128,824 -2,099 -4.5% $61.37 44,357 06 Jun 2022 Direct F1
transaction PCRX Common Stock Options Exercise $214,844 +6,250 +14% $34.38 50,607 06 Jun 2022 Direct F2
transaction PCRX Common Stock Sale $153,494 -2,535 -5% $60.55 48,072 06 Jun 2022 Direct F2, F3
transaction PCRX Common Stock Sale $141,657 -2,300 -4.8% $61.59 45,772 06 Jun 2022 Direct F2, F4
transaction PCRX Common Stock Sale $81,159 -1,300 -2.8% $62.43 44,472 06 Jun 2022 Direct F2, F5
transaction PCRX Common Stock Sale $7,291 -115 -0.26% $63.40 44,357 06 Jun 2022 Direct F2, F6
transaction PCRX Common Stock Sale $213,923 -3,533 -8% $60.55 40,824 06 Jun 2022 Direct F2, F7
transaction PCRX Common Stock Sale $224,804 -3,650 -8.9% $61.59 37,174 06 Jun 2022 Direct F2, F8
transaction PCRX Common Stock Sale $118,150 -1,891 -5.1% $62.48 35,283 06 Jun 2022 Direct F2, F9
transaction PCRX Common Stock Sale $7,834 -123 -0.35% $63.69 35,160 06 Jun 2022 Direct F2, F10
transaction PCRX Common Stock Award $0 +9,900 +28% $0.000000 45,060 08 Jun 2022 Direct F11

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCRX Stock Option (Right to Buy) Options Exercise $0 -6,250 -100% $0.000000* 0 06 Jun 2022 Common Stock 6,250 $34.38 Direct F12
transaction PCRX Stock Option (Right to Buy) Award $0 +24,800 $0.000000 24,800 08 Jun 2022 Common Stock 24,800 $59.39 Direct F13
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units.
F2 The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.23 to $61.22, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 3 through 10.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.23 to $62.17, inclusive.
F5 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.23 to $62.78, inclusive.
F6 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.29 to $64.14, inclusive.
F7 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.220 to $61.215, inclusive.
F8 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.22 to $62.18, inclusive.
F9 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.200 to $62.935, inclusive.
F10 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.60 to $64.06, inclusive.
F11 Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2023, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F12 The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date.
F13 The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.